Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up

A phase II randomized controlled trial assessed rucaparib maintenance therapy versus placebo in 79 patients with metastatic or recurrent endometrial cancer who had received 1-2 prior lines of therapy. The primary outcome was progression-free survival (PFS), with follow-up reported at 55.8 months. The study sponsor was the University of Colorado, Denver.

No specific efficacy results for the primary PFS outcome are reported in the provided data. Effect size, absolute numbers, p-values, and direction of effect are all listed as not reported. Secondary outcomes were not specified in the input.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuation rates, are also not reported in the provided information. No specific study limitations were listed in the input.

As a completed phase II trial, this research represents an early-stage investigation. The absence of reported efficacy and safety outcomes prevents any assessment of rucaparib's potential benefit-risk profile in this setting. Clinicians should await peer-reviewed publication of the full trial results before considering any practice implications.